# Adherence, Acceptability, and Sexual Health Outcomes of the Odeya App–Based Intervention for Sexual Distress in Women With Endometriosis: Randomized Controlled Mixed Methods Trial

**Authors:** Selina Marie Kronthaler, Eden Kosman, Tatjana Tissen-Diabaté, Elena Mühle, Luzia Weber- Schallauer, Therese Pross, Maria Margarete Karsten, Klaus Michael Beier, Laura Hatzler

PMC · DOI: 10.2196/86042 · Journal of Medical Internet Research · 2026-02-19

## TL;DR

A digital app called Odeya was tested to help women with endometriosis and sexual distress, showing some improvements in sexual health and mental well-being.

## Contribution

The study introduces a self-guided digital intervention for sexual distress in women with endometriosis and evaluates its adherence, acceptability, and outcomes.

## Key findings

- The Odeya app was well accepted, with high satisfaction scores from users.
- Participants in the intervention group showed greater improvements in sexual function and mental health compared to the control group.
- Emotional strain and technical issues were key barriers to adherence in the app-based intervention.

## Abstract

Evidence-based interventions effectively treat sexual dysfunctions. Up to 13.5% of women with gynecological conditions are affected, yet access to therapy is limited. Self-guided digital interventions may offer scalable, accessible first-line support.

This randomized controlled mixed methods pilot trial evaluated adherence, acceptance, and safety of the Odeya app and changes in sexual and health outcomes among women with sexual dysfunctions and endometriosis.

Following online and flyer-based recruitment, participants completed an online screening and were randomized to either an intervention group (IG) receiving 8 self-guided app modules targeting biopsychosocial aspects of sexuality or to a control group (CG) receiving routine care. Self-administered online questionnaires were completed at baseline (T0), midintervention (T1), postintervention (T2), and 6-month follow-up (T3). Standardized instruments assessed acceptance (Client Satisfaction Questionnaire-Internet [CSQ-I] and German mHealth App Usability Questionnaire [G-MAUQ]), safety (Inventory for the balanced assessment of Negative Effects of Psychotherapy-Online Intervention), sexual health (Female Sexual Distress Scale-Desire/Arousal/Orgasm [FSDS-DAO], Female Sexual Function Index-German version [FSFI-d], and Partnership Questionnaire), and overall health (Patient-Reported Outcome Measurement Information System-29-Item Profile, Beck Depression Inventory-II, and Generalized Anxiety Disorder-7). Adherence indicators included module completion, dropout rates, and symptom tracker use. Group differences were examined descriptively and using Cohen d. Qualitative data were collected through free-list questionnaires from dropouts (n=11) and interviews with completers (IG: n=3; CG: n=2).

A total of 60 women (mean age 31.12, SD 6.67 years) with confirmed or suspected endometriosis and sexual distress (FSDS-DAO score >18) were randomized to the IG (n=29) or CG (n=31). IG participants completed on average 61.2% (4.9/8) of modules; the dropout rate was 65.5% (19/29). Emotional strain, time demands, and technical issues were key barriers causing dropout, while persona-based stories facilitated engagement. Participants wished for more professional interaction. IG completers (n=10, 34.5%) showed lower baseline depression and anxiety but higher sexual distress. Satisfaction was high (CSQ-I=26.60; G-MAUQ=5.38). Although some adverse health changes were reported, findings indicate safety. FSDS-DAO scores decreased in both groups, with mean reductions from baseline of −10.39, −12.61, and −14.98 in the IG and −3.68, −14.83, and −6.92 in the CG from T1 to T3, respectively. Moderate to large between-group effects favoring the IG were observed at T1 (d=−0.66) and T3 (d=−0.79). Sexual function (FSFI-d) improved only in the IG (T1-T3: d=0.16-1.00). Qualitative findings highlighted rediscovery of positive sexual experiences, improved communication, and increased openness. Both groups reported improvements in anxiety, depression, and physical functioning, with additional gains in emotion regulation, distress reduction, and body awareness reported in the IG. Women emphasized symptom complexity and a need for more professional guidance.

The self-guided intervention was well accepted and showed preliminary improvements among completers. Adherence and sustained engagement seemed shaped by baseline psychosocial health, pointing to a need for tailored adaptations and larger confirmatory trials.

German Clinical Trials Register DRKS00034351; https://drks.de/search/en/trial/DRKS00034351

## Linked entities

- **Diseases:** endometriosis (MONDO:0005133)

## Full-text entities

- **Genes:** CHKA (choline kinase alpha) [NCBI Gene 1119] {aka CHK, CK, CKI, EK, NEDMIMS}
- **Diseases:** adenomyosis (MESH:D062788), cardiac arrhythmia (MESH:D001145), fatigue (MESH:D005221), lipedema (MESH:D065134), PTSD (MESH:D013313), bladder problems (MESH:D001745), Distress (MESH:D012128), premenstrual syndrome (MESH:D011293), REDCap (MESH:D014947), bowel problems (MESH:D012778), Pain (MESH:D010146), Endometriosis (MESH:D004715), Mental Disorders (MESH:D001523), substance dependence (MESH:D019966), cancer (MESH:D009369), problems in sexual function (MESH:D050035), Sexual dysfunctions (MESH:D012735), Fear of coitus (MESH:C000719212), disruptive behavior (MESH:D019958), Anxiety (MESH:D001007), asthma (MESH:D001249), Depression (MESH:D003866), chronic pain (MESH:D059350), DSM-IV (MESH:D006011), incontinence (MESH:D014549), Problems (MESH:D019973), migraine (MESH:D008881), Chronic diseases (MESH:D002908), dissociative symptoms (MESH:D004213), chronic infections (MESH:D000088562), Symptom (MESH:D012816), Generalized Anxiety Disorder (MESH:C000726808), polycystic ovary syndrome (MESH:D011085), Vaginismus (MESH:D052065), genito-pelvic pain/penetration disorder (MESH:D017699), dyspareunia (MESH:D004414), psychosis (MESH:D011618), -29 (OMIM:614890), mental health symptoms (OMIM:603663), erectile dysfunction (MESH:D007172)
- **Chemicals:** LH (MESH:D007986), CSQ-I (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** PROMIS-29 — Homo sapiens (Human), Amyotrophic lateral sclerosis 1, Induced pluripotent stem cell (CVCL_8999)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963981/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963981/full.md

## References

160 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963981/full.md

---
Source: https://tomesphere.com/paper/PMC12963981